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Plasma N-Terminal Probrain Natriuretic Peptide, Vascular
Endothelial Growth Factor, and Cardiac Troponin I as Novel
Biomarkers of Hypertensive Disease and Target Organ Damage in
Cats
E.S. Bijsmans, R.E. Jepson, C. Wheeler, H.M. Syme, and J. Elliott
Background: In the absence of ocular target organ damage (ocular-TOD), diagnosis of hypertension is challenging in cats.
Biomarkers would provide additional support for the diagnosis of hypertension.
Hypothesis: Vascular endothelial growth factor (VEGF), N-terminal probrain natriuretic peptide (NT-proBNP), cardiac
troponin I (cTnI), and urine protein-to-creatinine ratio (UPC) are predictors of systemic hypertension, will be increased in
cats with hypertension with or without ocular-TOD, and will decrease with antihypertensive treatment.
Methods: Plasma VEGF, NT-proBNP, and cTnI concentrations and UPC were determined in healthy geriatric cats, nor-
motensive cats with chronic kidney disease (CKD), hypertensive cats with evidence of hypertensive retinopathy (HT-ocular-
TOD), and hypertensive cats without hypertensive ocular-TOD (HT-noTOD). Comparisons among groups were performed.
Multivariable binary logistic regression models were built to identify independent biomarkers of hypertension and ocular-
TOD. Receiver operator characteristic (ROC) curves were drawn to assess clinical use.
Results: Cats with HT-ocular-TOD had significantly higher VEGF than all other groups (P < .05) and significantly higher
NT-proBNP than healthy cats (P < .001). Healthy cats had significantly lower cTnI than all other groups (P < .05). No dif-
ferences were found among groups for UPC (P = .08). Cardiac troponin I and VEGF were independent predictors of hyper-
tension (P < .05), but none of the biomarkers were independent predictors of ocular-TOD. N-terminal probrain natriuretic
peptide concentrations decreased with antihypertensive treatment (P < .001). The ROC curves indicated that none of the
biomarkers met the criteria to function as diagnostic tests for the diagnosis of hypertension or associated ocular-TOD.
Conclusions and Clinical Significance: Despite statistical significance and changes with ocular-TOD, antihypertensive treat-
ment, or both, VEGF, NT-proBNP, and cTnI did not function as useful diagnostic tests for hypertension. Persistently
increased systolic blood pressure (SBP) measurements in combination with fundoscopy remains the preferred method for
diagnosis of feline hypertension.
Key words: Chronic kidney disease; Hypertension.
White coat hypertension is reported to occur fre-quently in cats, with systolic blood pressure
(SBP) increasing on average 22.3 mmHg during clinical
examination, but with a highly unpredictable interindi-
vidual effect and SBP increasing by as much as
75 mmHg in some cats.1 Without evidence of hyperten-
sive retinopathy (ocular target organ damage [ocular-
TOD]), it therefore can be challenging to diagnose
hypertension, and clinicians must rely on documenta-
tion of consistently high SBP measurements in affected
cats.2 Hypertension has many immediate effects on the
body and results in several physiologic responses in an
attempt to decrease blood pressure. In hypertensive
human patients, a number of these physiologic
responses have been shown to involve substances that
could function as biomarkers of hypertension, hyperten-
sive TOD, efficacy of treatment, or some combination
of these. The heart and blood vessels are considered tar-
get organs of hypertensive damage in both humans and
cats.2 Vascular endothelial growth factor (VEGF)
secreted by endothelial cells and N-terminal pro-B-type
natriuretic peptide (NT-proBNP) and cardiac troponin
I (cTnI) secreted by cardiomyocytes are examples of
biomarkers that have been investigated for use in
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hypertensive human patients.3,4 Urine protein-to crea-
tinine ratio (UPC) is a potential marker of TOD and
renal injury.5,6 Increased blood pressure leads to
increased glomerular pressure and therefore leakage of
protein into the urine. The UPC has been shown to be
increased in hypertensive cats when compared to
normotensive cats.7
Vascular endothelial growth factor is secreted in
response to shear stress of endothelial cells8 and
mechanical stretch of vascular smooth muscle cells.9
Plasma VEGF concentrations are increased in human
patients with hypertension3,10 and in patients with
hypertensive retinopathy.11 In addition, plasma VEGF
decreases with antihypertensive treatment in humans.12
Concentrations of NT-proBNP are increased in hyper-
tensive human patients with peripheral arterial disease.4
Human subjects with poor blood pressure control have
higher plasma NT-proBNP concentrations, indicating
its potential use as a marker for effectiveness of
treatment.13 Cats with hypertension and evidence of
ocular-TOD have significantly higher NT-proBNP
concentrations than do healthy cats and those with
normotensive chronic kidney disease (CKD).14 Hyper-
tensive cats have been reported to have lower concen-
trations of NT-proBNP if hypertension is not
accompanied by ocular-TOD, although these cats also
had significantly lower blood pressure than did their
counterparts with evidence of ocular changes.15 Car-
diac troponin I is produced only by cardiomyocytes and
is a sensitive and specific marker of myocardial cell
necrosis in humans16 and dogs.17 Cats with hyper-
trophic cardiomyopathy (HCM) have increased cTnI
concentrations.18 During hypoxic stress, cardiomyocytes
release cTnI,16 and it is possible that cTnI also is released
when hypertension causes hypertrophy, stretch, strain, or
damage. Human patients admitted to hospital for severe
hypertension often have increased cTnI concentrations.19
The aims of our study were to assess UPC, VEGF,
NT-proBNP, and cTnI as potential biomarkers of
hypertension in cats with and without ocular-TOD, and
to assess whether VEGF, NT-proBNP, and cTnI are
informative in terms of assessment of blood pressure
control.
Materials and Methods
Clinics and Case Selection
Cats diagnosed with hypertension at 2 first opinion practices in
central London (People’s Dispensary for Sick Animals in Bow and
Beaumont Sainsbury Animal Hospital in Camden) between May
2007 and July 2015 were retrospectively identified. A standardized
visit protocol was followed for each cat, which included full his-
tory and physical examination. A noninvasive Doppler techniquea
was used to measure SBP after a period of acclimatization. Aver-
age SBP was calculated from 5 consecutive readings after discard-
ing the first reading. If average SBP was ≥160 mmHg, indirect
fundoscopy was performed by the attending clinician with an inde-
pendent light source and a lens, after applying 1 drop of tropi-
camide 1% to both eyes.
At the first visit to the clinic, informed owner consent was
obtained to collect blood samples by jugular venipuncture and
urine samples by cystocentesis. The standard clinic protocols,
information sheets, and consent forms for use of residual samples
for research were approved by the Royal Veterinary College’s
Ethics and Welfare Committee. Blood samples were collected into
lithium heparin tubes and EDTA tubes and held on ice (4°C) for a
maximum of 6 hours before centrifugationb and separation.
Plasma biochemistry was performed at an external laboratory.c
Not all cats included in this study had serum total thyroxine
(TT4) concentration measured, but cases were excluded if they had
a TT4 > 40 nmol/L (reference range, 10–55 nmol/L), had clinical
signs consistent with hyperthyroidism (eg, polyphagia, weight loss,
palpable goiter, tachycardia), or were currently undergoing treat-
ment for hyperthyroidism. Cats also were excluded if they had evi-
dence of other concurrent disease (eg, palpation of an abdominal
mass) and if they were on medications that were likely to alter
blood pressure (eg, benazepril). Urine protein-to-creatinine ratios
were determined at the same laboratory that was used for plasma
biochemistry and TT4 measurements, and urine samples from cats
with evidence of a urinary tract infection were excluded from
analysis.
Four groups were included: cats diagnosed with azotemic
CKD (CKD), healthy geriatric cats (Healthy), hypertensive cats
with evidence of ocular hypertensive TOD (HT-ocular-TOD),
and hypertensive cats without evidence of hypertensive retinopa-
thy (HT-noTOD). The hypertensive visit for the HT-ocular-TOD
and HT-noTOD groups and 1 visit for the CKD and healthy
groups were used for the cross-sectional analyses. Azotemic
CKD was diagnosed based on a plasma creatinine concentration
≥2.0 mg/dL either on 2 consecutive visits or on a single occasion
if in conjunction with urine specific gravity (USG) <1.035.
Healthy cats had unremarkable history and physical examina-
tion, SBP <160 mmHg, and plasma biochemistry lacked abnor-
malities deemed to be clinically relevant by the attending
clinician. Cats that had urine samples available and USG <1.035
were only included as healthy if they had follow-up visits at
which the cat was assessed as healthy by the attending clinician
and no azotemia developed within 6 months. All cats included in
the HT-ocular-TOD group had SBP ≥160 mmHg and evidence
of hypertensive retinopathy or choroidopathy on indirect oph-
thalmologic examination, whereas all cats included in the HT-
noTOD group were diagnosed based on a SBP ≥170 mmHg on
2 consecutive visits, but did not have evidence of ocular hyper-
tensive TOD. A small number of the cats had undergone
echocardiographic assessment, but to prevent bias in the selec-
tion, the authors were blinded to the results of the cardiac
evaluation.
Only hypertensive cats were included in the longitudinal study.
All hypertensive cats were treated with amlodipine besylate.d A
blood sample was taken at the time of diagnosis of hypertension
(included in the cross-sectional study), at the first visit antihyper-
tensive control was achieved (defined as SBP <160 mmHg and
receiving 0.625–1.25 mg amlodipine/cat/day) and approximately
4 months later (approximately 5 months after diagnosis of hyper-
tension). All cats must have had residual stored heparinized
plasma and EDTA plasma samples available for all visits included
in both the cross-sectional and longitudinal studies to be eligible
for inclusion.
Measurement of UPC, VEGF, NT-proBNP, and cTnI
The VEGF assay validated in this study was a commercially
available canine VEGF ELISA.e Precision and reproducibility of
the assay for heparinized feline plasma samples were determined
by calculating intra- and interassay coefficients of variation (CV).
Dilutional parallelism was assessed, as was the effect of 4 freeze-
thaw cycles.
Plasma EDTA samples previously stored at 80°C were used
for batch analysis of NT-proBNP and cTnI at a commercial
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laboratory.c Batch analysis of UPC on urine samples previously
stored at 80°C was performed at the same laboratory. The UPC
was only determined for samples included in the cross-sectional
study, and not post-treatment with amlodipine in the hypertensive
groups.
Statistical Analyses
Statistical analyses were performed by 2 different statistical soft-
ware packages.f Results are presented as median [25th, 75th per-
centiles], and statistical significance was determined as P < .05.
Variables were assessed for normality by visual inspection of his-
tograms. The number of cats that was needed for the cross-sec-
tional study was estimated by a parametric power calculation on
unpublished VEGF data on healthy cats and hypertensive cats
without ocular-TOD, and estimated data for cats with ocular-
TOD, with power set at 80% and significance at 5%. This power
calculation was repeated after all measurements were performed,
and an actual mean concentration was known for ocular-TOD
cats. The parametric power calculation was adjusted for the fact
that the data were skewed by multiplying it by 1.15 (15% addi-
tional cats).
Cross-sectional comparisons among HT-ocular-TOD, HT-
noTOD, CKD, and healthy cats were made using Kruskal–Wallis
tests with posthoc comparisons by Dunn’s test or a 1-way
ANOVA with posthoc Tukey’s test. The proportion of cats with
concurrent CKD was compared between HT-ocular-TOD and
HT-noTOD using Fisher’s exact test. Comparisons among related
visits within the hypertensive groups were made using the non-
parametric Wilcoxon signed-rank test and Friedman test with
posthoc comparisons using the Bonferroni method.
To identify predictors of hypertension, HT-ocular-TOD and
HT-noTOD were grouped as hypertensive, and the healthy cats
and cats with CKD functioned as the control group. To identify
predictors of ocular-TOD, the HT-noTOD cats functioned as the
control group and were compared to the cats with HT-ocular-
TOD. Plasma VEGF, NT-proBNP, and cTnI concentrations and
UPC all were included as explanatory variables in univariable bin-
ary logistic regression models with hypertension or ocular-TOD as
dependent variable. All variables were log-transformed to meet
normality criteria. Variables significant at the 20% level were
included in a multivariable binary logistic regression to identify
the biomarkers that were independent predictors of hypertension
and ocular-TOD.
Receiver operating characteristic curves (ROC) were used to
determine whether VEGF, NT-proBNP, cTnI, and UPC could be
used to predict hypertension and ocular-TOD in a clinical setting.
Sensitivity and specificity were used to describe potential cutoffs
for the variables that had an area under the curve (AUC) signifi-
cantly >0.5. The combined use of VEGF, NT-proBNP, and cTnI
to diagnose hypertension or ocular-TOD was explored. The cutoff
value for each variable was determined based on the greatest com-
bined sensitivity and specificity. Sensitivity and specificity were
determined using each possible combination of the significant val-
ues to diagnose hypertension and ocular-TOD.
Results
Validation of the Canine VEGF ELISA for Feline
Plasma
The intra-assay CVs for samples measuring 99.5,
100.9, and 101.5 pg/mL were 9.9, 5.0, and 4.5%, respec-
tively. The interassay CVs for samples measuring 63.2,
100.3, and 109.5 pg/mL were 13.9, 7.2 and 4.3%,
respectively. Dilutional parallelism was demonstrated:
94.9 (13.6) % recovery. Measurement after 4 freeze-
thaw cycles gave a recovery of 119.4 (4.3) % (n = 3).
Subjects
The power calculation indicated 25 cats were needed
per group. A total of 25 hypertensive cats with ocular-
TOD, 24 hypertensive cats without ocular-TOD, 25
healthy cats, and 25 CKD cats were included
(Table 1). As expected, both hypertensive groups had
significantly higher SBP than did the healthy and CKD
cats. The healthy cats were significantly younger and
had lower plasma urea and creatinine concentrations,
and higher USG than all other groups. Three healthy
cats had USG <1.035 at the included visit. All 3 had
follow-up visits at which they remained nonazotemic
and were deemed healthy by the attending veterinarian.
Two of these cats had urine samples available at fol-
low-up visits, and both had concentrated urine at those
visits. Twenty-nine cats had NT-proBNP >270 pmol/L,
which makes cardiac disease more likely (http://www.
idexx.co.uk/pdf/en_gb/smallanimal/reference-laboratorie
s/clinical-guidance-cardiac-disease.pdf, downloaded on
21/09/2015). Twelve cats with NT-proBNP>270 pmol/L
had an echocardiographic result available, of which 4
were classified as normal (1 in the HT-ocular-TOD
group; 3 in the CKD group), 5 had evidence of severe
hypertrophy (3 in the HT-noTOD group, all were
already on amlodipine treatment at the time of
echocardiography; 2 had CKD), 1 had pseudohypertro-
phy likely because of dehydration (HT-ocular-TOD
group, echocardiography was performed on the day
hypertension was diagnosed), 1 had possible left ven-
tricular hypertrophy (CKD group), and 1 cat had
dynamic left ventricular outflow tract obstruction (HT-
noTOD group, echocardiography performed on the
day hypertension was diagnosed). The majority of cats
(n = 88) did not have an echocardiographic assessment
available.
Vascular Endothelial Growth Factor, NT-proBNP,
cTnI, and UPC as Predictors of Hypertension and
Ocular-TOD
Univariable Analyses. Comparison among groups
determined that HT-ocular-TOD had significantly
higher plasma VEGF concentrations than did HT-
noTOD, CKD, and healthy cats (P < .05; Fig 1). The
power calculation with the actual values indicated that
35 cats were needed per group to show a potential dif-
ference between HT-ocular-TOD and HT-noTOD. A
sample size of 58 per group would be needed to detect
a decrease of 20% in response to treatment when
grouping HT-ocular-TOD and HT-noTOD, assuming a
standard deviation (SD) of 46 on the change in VEGF
with treatment (80% power with significance set at
5%). Univariable binary logistic regression indicated
that log-transformed plasma VEGF concentration was
a positive predictor of hypertension (P < .05; Table 2).
The ROC curve indicated that plasma VEGF could be
used to predict hypertension (AUC, 0.64; P = .016)
Biomarkers of Feline Hypertension 3
with an optimal value of >76.1 pg/mL (specificity, 72%;
sensitivity, 59%). Concentrations of VEGF were found
to be a positive and significant predictor of ocular-TOD
in the univariable analysis (P = .01; Table 3). The cutoff
to diagnose ocular-TOD was defined at >71.6 pg/mL
(AUC, 0.73; sensitivity, 80%; specificity, 62.5%;
P < .01).
Plasma NT-proBNP concentration was found to be
significantly higher in HT-ocular-TOD when compared
with healthy cats (P < .001; Fig 2). Log-transformed
plasma NT-proBNP concentration was a positive pre-
dictor of hypertension in the univariable analysis
(P < .01; Table 2). The optimum cut-point for NT-
proBNP to predict hypertension was >134.5 pmol/L
(AUC, 0.68; sensitivity, 59%; specificity, 72%;
P = .002). Log-transformed NT-proBNP was not a sig-
nificant predictor of ocular-TOD in the univariable
analysis (P = .167; Table 3). The ROC had an AUC
that was not significantly different from the line of zero
discrimination (AUC = 0.64, P = .08). A cutoff point
for using NT-proBNP to predict ocular-TOD therefore
was not determined.
Plasma cTnI concentration was significantly lower in
healthy cats when compared with HT-ocular-TOD, HT-
noTOD, and CKD (Fig 3). Log-transformed cTnI was
a positive significant predictor of hypertension in the
univariable analysis (P < .001; Table 2). The ROC
curve indicated that the cutoff value for cTnI to deter-
mine hypertension to be >0.045 ng/mL (AUC, 0.73;
sensitivity, 63%; specificity, 78%; P < .0001). Plasma
cTnI concentration was significantly associated with
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Fig 1. Plasma vascular endothelial growth factor (VEGF) con-
centration in healthy cats (n = 25), cats with chronic kidney dis-
ease (n = 25), hypertensive cats without evidence of hypertensive
ocular target organ damage (HT-noTOD) (n = 24), and hyperten-
sive cats with evidence of hypertensive retinopathy (HT-ocular-
TOD) (n = 25). HT-ocular-TOD had significantly higher plasma
VEGF concentration than all other groups (P < .05 for all
comparisons).
Table 1. Clinicopathologic variables for healthy, CKD, HT-ocular-TOD, and HT-noTOD cats.
Healthy (n = 25) CKD (n = 25) HT-noTOD (n = 24) HT-Ocular-TOD (n = 25)
VEGF (pg/mL) 49.4 [39.0, 94.4]a 70.4 [51.2, 78.5]a 53.3 [39.9, 106.6]a 105.6 [77.3, 142.5]b
NT-proBNP (pmol/L) 67.0 [28.5, 118.0]a 126.0 [75.0, 290.5]ab 120.0 [75.0, 289.0]ab 236.0 [114.5, 519.0]b
cTnI (ng/mL) 0.02 [0.01, 0.03]a 0.04 [0.02, 0.05]b 0.04 [0.02, 0.06]b 0.07 [0.05, 0.14]b
SBP (mmHg) 131.2 [113.0, 139.4]a 136.0 [133.2, 141.4]a 179.4 [175.3, 188.2]b 184.8 [168.4, 203.6]b
UPC 0.18 [0.13, 0.22] 0.24 [0.15, 0.58] 0.25 [0.20, 0.50] 0.17 [0.14, 0.30]
Heart rate (bpm) 180 [165, 199] 192 [180, 210] 180.0 [180.0, 204.0] 182 [164, 205]
Age (years) 12.1 [11.1, 13.2]a 15.3 [12.4, 16.7]ab 15.3 [12.8, 17.0]b 15.8 [13.5, 18.0]b
Weight (kg) 4.5 [3.8, 5.4]a 3.8 [3.3, 4.6]bc 4.6 [3.5, 5.7]ab 3.6 [3.0, 4.4]c
PCV (%) 36 [34, 40] 35 [29, 39] 37 [34, 40] 35 [30, 39]
Albumin (g/dL) 3.2 [3.0, 3.3] 3.1 [3.0, 3.2] 3.3 [3.1, 3.4] 3.1 [2.9, 3.3]
Creatinine (mg/dL) 1.4 [1.3, 1.6]a 2.4 [2.1, 2.9]b 2.1 [1.7, 2.9]b 2.3 [1.6, 2.8]b
Urea (mmol/L) 9.6 [8.1, 11.4]a 15.0 [12.5, 19.2]b 15.8 [11.8, 21.6]b 16.2 [11.4, 22.3]b
Phosphate (mg/dL) 3.56 [3.25, 4.15] 3.62 [3.28, 4.30] 4.09 [3.34, 4.74] 3.84 [3.34, 4.92]
Total calcium (mg/dL) 9.8 [9.5, 10.2] 10.4 [9.8, 11.1] 10.0 [9.8, 10.4] 10.0 [9.5, 10.6]
Sodium (mEq/L) 153.7 [152.5, 154.7] 155.8 [153.5, 157.6] 154.1 [151.3, 156.5] 154.2 [152.3, 156.7]
Potassium (mEq/L) 4.1 [3.7, 4.3] 4.1 [3.8, 4.3] 4.1 [3.7, 4.5] 4.0 [3.7, 4.3]
Chloride (mEq/L) 119.6 [118.2, 122.5]a 119.7 [118.1, 120.9]ab 117.5 [115.3, 119.7]b 118.8 [116.3, 120.3]ab
Cholesterol (mmol/L) 181.5 [142.9, 212.4] 223.9 [181.5, 278.0] 202.3 [177.6, 239.4] 200.8 [179.5, 219.3]
USG 1.047 [1.036, 1.057]a 1.018 [1.017, 1.024]b 1.018 [1.015,1.028]b 1.019 [1.016, 1.025]b
CKD, chronic kidney disease; HT-ocular-TOD, hypertensive cats with evidence of ocular target organ damage; HT-noTOD, hypertensive
cats without evidence of ocular target organ damage; VEGF, vascular endothelial growth factor; NT-proBNP, N-terminal probrain natri-
uretic peptide; cTnI, cardiac troponin I; UPC, urine protein-to-creatinine ratio; SBP, systolic blood pressure; PCV, packed cell volume;
USG, urine specific gravity.
Comparisons between groups were performed using a Kruskal–Wallis with posthoc Dunn’s test or 1-Way ANOVA with posthoc Tukey’s
test. Medians bearing the same superscript letter are not significantly different from one another. All values are presented as median [25th,
75th percentiles].
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ocular-TOD in the univariable analysis (P = .028;
Table 3). The drawn ROC curve indicated that cTnI
could be used to predict ocular-TOD, with a cutoff
value of >0.045 pg/mL (AUC = 0.71; sensitivity, 84%;
specificity, 58%; P = .01).
The UPC was not found to be different among
groups (Fig 4). Log-transformed UPC was not a signifi-
cant predictor of hypertension in the univariable analy-
sis (P = .47; Table 2). The ROC for determination of
hypertension therefore was not drawn. The UPC was
associated with ocular-TOD at the 20% level in the uni-
variable analysis (P = .118; Table 3). However, the
ROC curve indicated that UPC could not be used to
predict ocular-TOD (AUC = 0.67, P = .14).
Multivariable Analyses. Plasma VEGF, NT-proBNP,
and cTnI concentrations all were predictive of hyperten-
sion at the 20% level in the univariable logistic regres-
sion and were included in the multivariable model. This
indicated that log-transformed plasma VEGF and cTnI
concentrations remained significant and positive predic-
tors of hypertension (Table 4). A 10-fold increase in
plasma VEGF concentration was associated with an
odds ratio (OR) of 2.16 (95% confidence interval [CI],
1.06–4.65; P < .05), and a 10-fold increase in plasma
cTnI concentration had an OR of 2.38 (95% CI, 1.17–
5.28; P < .05).
All 4 variables were significant at the 20% level to
predict ocular-TOD and therefore were included in the
multivariable analysis. None of the variables remained
significantly associated with ocular-TOD (Table 5).
The ROC curves indicated that cTnI had the highest
specificity for diagnosing hypertension (78%). The UPC
could not reliably diagnose hypertension, and only com-
binations of cTnI, VEGF, and NT-proBNP were
Table 2. Univariable analysis of VEGF, NT-proBNP,
and cTnI as predictors of hypertension in cats.
Variable n b SE P-Value 95% CI for b
log(cTnI) 99 0.814 0.237 .0006 0.375 to 1.311
log(NT-proBNP) 99 0.565 0.200 .0046 0.190 to 0.978
log(VEGF) 99 0.843 0.351 .0164 0.185 to 1.574
log(UPC) 50 0.310 0.429 .4700 0.519 to 1.199
VEGF, vascular endothelial growth factor; NT-proBNP, N-
terminal probrain natriuretic peptide; cTnI, cardiac troponin I;
UPC, urine protein-to-creatinine ratio; n, number of cats; 95% CI,
95% confidence interval.
Log(cTnI), log(NT-proBNP), and log(VEGF) were significant at
the 20% level and included in the multivariable analysis.
Table 3. Univariable analysis of VEGF, NT-proBNP,
and cTnI as predictors of TOD in cats.
Variable n b SE P-Value 95% CI for b
log(VEGF) 49 1.405 0.546 .01 0.426 to 2.594
log(cTnI) 49 0.770 0.350 .028 0.136 to 1.528
log(UPC) 27 1.034 0.660 .118 0.153 to 2.518
log(NT-proBNP) 49 0.3853 0.279 .167 0.145 to 0.966
VEGF, vascular endothelial growth factor; NT-proBNP, N-
terminal probrain natriuretic peptide; cTnI, cardiac troponin I,
UPC; urine protein-to-creatinine ratio; n, number of cats; 95% CI,
95% confidence interval.
All 4 variables were significant at the 20% level and included in
the multivariable analysis.
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Fig 2. Plasma N-terminal probrain natriuretic peptide
(NT-proBNP) concentrations in healthy cats, (n = 25), cats with
chronic kidney disease (n = 25), hypertensive cats without evidence
of hypertensive ocular target organ damage (HT-noTOD)
(n = 24), and hypertensive cats with evidence of hypertensive
retinopathy (HT-ocular-TOD) (n = 25). HT-TOD had significantly
higher plasma NT-proBNP concentration than healthy cats
(P < .001).
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Fig 3. Plasma cardiac troponin I (cTnI) concentrations in healthy
cats, (n = 25), cats with chronic kidney disease (n = 25), hyperten-
sive cats without evidence of hypertensive ocular target organ
damage (HT-noTOD) (n = 24), and hypertensive cats with evi-
dence of hypertensive retinopathy (HT-ocular-TOD) (n = 25).
Healthy cats had significantly lower plasma cTnI concentrations
than all other groups (P < .05).
Biomarkers of Feline Hypertension 5
explored. Using a combination of VEGF and either
NT-proBNP or cTnI, specificity of 94% could be
achieved, with sensitivity of 37% and 45%, respectively.
The specificity could be increased to 96% by incorpo-
rating all 3 variables, which was associated with a
decrease in sensitivity to 31%.
Assessment of the ROC curves indicated that NT-
proBNP concentration and UPC could not reliably be
used to diagnose ocular-TOD, and therefore, only the
combination of VEGF and cTnI was explored for this
purpose. Plasma cTnI concentration >0.045 pg/mL in
combination with plasma VEGF concentration
>71.6 pg/mL had a specificity of 88% to diagnose
ocular-TOD; sensitivity was 76%.
Changes in VEGF, NT-proBNP, and cTnI With Treat-
ment of Hypertension. Cats with HT-ocular-TOD had
received amlodipine for 20  8 days, and HT-noTOD
for 25  15 days at the first controlled visit. The third
visit was 141  43 days after starting treatment for the
HT-ocular-TOD group and 157  42 days for the HT-
noTOD group. At the diagnosis of hypertension, 20
cats in the HT-ocular-TOD group and 16 cats in the
HT-noTOD group had concurrent CKD (P = .35).
Plasma creatinine concentration did not significantly
change over the course of 5 months (P = .58), and no
cats showed evidence of CKD progression (defined as a
>25% increase in plasma creatinine concentration).
At the hypertensive visit, median plasma VEGF con-
centration in the HT-ocular-TOD group was 105.6
[77.30, 142.5] pg/mL. At the first controlled visit, the
median concentration was 91.0 [64.2, 162.7] pg/mL, and
at visit 3, the concentration was 86.2 [64.0, 124.7] pg/
mL. No significant change over time was found
(P = .07). The VEGF concentration for the HT-noTOD
group was 53.3 [39.9, 106.6] pg/mL at baseline, and
62.4 [45.8, 105.3] pg/mL at the first controlled visit, fol-
lowed by a concentration of 54.3 [38.6, 105.3] at visit 3
(not significant, P = .19).
Because of financial considerations, NT-proBNP con-
centrations from both the hypertensive visit and the first
controlled visit were determined initially, before making
a decision with regard to measuring the sample concen-
tration of a visit after approximately 5 months of
amlodipine treatment. In HT-ocular-TOD, NT-proBNP
concentration decreased significantly with approxi-
mately 2 weeks of amlodipine treatment, from 236.0
[114.5, 519.0] pmol/L to 94.0 [56.0, 245.5] pmol/L
(P < .001). The NT-proBNP concentration also signifi-
cantly decreased in the HT-noTOD-group, from 120.0
[75.0, 289.0] pmol/L to 78.0 [55.0, 192.8] pmol/L
(P < .001; Fig 5). Because NT-proBNP showed a signif-
icant decrease at the first controlled visit, this marker
was not measured after 5 months of antihypertensive
treatment.
Plasma cTnI concentration did not significantly
change with antihypertensive treatment in either group
(HT-ocular-TOD: hypertensive visit, 0.07 [0.05, 0.14]
ng/mL; first controlled visit, 0.06 [0.04, 0.12] ng/mL;
after approximately 5 months of treatment, 0.07 [0.05,
0.13] ng/mL; P = .25); HT-noTOD: hypertensive visit,
0.04 [0.02, 0.06] ng/mL; first controlled visit, 0.04 [0.03,
0.11] ng/mL; after approximately 5 months of treat-
ment, 0.05 [0.03, 0.08] ng/mL; P = .48).
Discussion
Plasma VEGF and cTnI concentrations were found
to be independent predictors of hypertension. Plasma
NT-proBNP decreased significantly with antihyperten-
sive treatment. These results seem promising for the use
Healthy CKD noTOD TOD
0.0
0.5
1.0
1.5
U
P
C
Fig 4. Urine protein-to-creatinine ratio (UPC) in healthy cats,
(n = 13), cats with chronic kidney disease (n = 10), hypertensive
cats without evidence of hypertensive ocular target organ damage
(HT-noTOD) (n = 14), and hypertensive cats with evidence of
hypertensive retinopathy (HT-ocular-TOD) (n = 13). No signifi-
cant differences were found between groups.
Table 4. Multivariable analysis including VEGF, NT-
proBNP, and cTnI to identify independent predictors of
hypertension in cats.
Variable b SE P-Value 95% CI for b
log(cTnI) 0.866 0.380 .023 0.157 to 1.663
log(VEGF) 0.768 0.373 .04 0.059 to 1.536
log(NT-proBNP) 0.102 0.334 .761 0.777 to 0.546
(Intercept) 0.006 2.970 .998 5.815 to 5.958
cTnI, cardiac troponin I; NT-proBNP, N-terminal probrain
natriuretic peptide; VEGF, vascular endothelial growth factor; n,
number of cats; 95% CI, 95% confidence interval.
Both cTnI and VEGF remained independent positive predictors
of hypertension in the multivariable analysis.
Table 5. Multivariable analysis including VEGF, NT-
proBNP, and cTnI to identify independent predictors of
TOD in cats.
Variable b SE P-Value 95% CI for b
log(VEGF) 1.520 0.794 .056 0.155 to 3.389
log(cTnI) 1.526 0.970 .115 0.150 to 3.768
log(NT-proBNP) 0.424 0.736 .564 1.956 to 1.038
log(UPC) 0.428 0.802 .594 1.076 to 2.224
(Intercept) 0.113 6.688 .987 13.96 to 13.25
VEGF, vascular endothelial growth factor; cTnI, cardiac tro-
ponin I; NT-proBNP, N-terminal probrain natriuretic peptide,
UPC, urine protein-to-creatinine ratio; 95% CI, 95% confidence
interval; TOD, target organ damage.
No independent positive or negative predictors of ocular-TOD
were found.
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of these markers for the diagnosis and management of
hypertension, but the ROC curves indicated that all
markers evaluated had fairly low sensitivity. Addition-
ally, all groups had substantial overlap in VEGF, NT-
proBNP, and cTnI concentrations, making the markers
less able to differentiate among groups. The power cal-
culation that was performed using the VEGF concen-
trations indicated that a larger sample size could have
led to significant results. The cats included in the cur-
rent study were diagnosed with hypertension based on
either high SBP with evidence of ocular-TOD or had
persistently high SBPs >170 mmHg. The groups were
chosen in such a way to be able to identify markers of
definitive hypertension and ocular-TOD.2 The repeat-
edly high SBP in some cats without ocular-TOD may
or may not have been because of white coat hyperten-
sion, which is a limitation that is challenging to man-
age. Use of biomarkers would therefore be an attractive
alternative to the current way of diagnosing hyperten-
sion by repeated blood pressure measurements.
The UPC previously has been shown to be increased
in hypertensive cats.7 Additionally, UPC can be
increased in CKD and is a predictor of CKD progres-
sion.6 The fact that most of the hypertensive cats
included in the current study had concurrent CKD
therefore may be an explanation for why this marker
was not found to be a significant predictor of hyperten-
sion or ocular-TOD. Only half of the included cats had
a palpable bladder and therefore a urine sample avail-
able for UPC measurement. The smaller sample size
therefore also could explain the lack of significance.
However, the UPC distribution was fairly atypical, with
25% of normotensive CKD cases having UPC of 0.58,
and 25% of healthy cats having UPC ≥0.22. Why this
distribution occurred in the current group is unclear,
but possibly because of the low number of cats. None
of the included cases had urinary tract infection.
One consideration is the speed with which the con-
centrations of these markers change in response to
increases in blood pressure in cats, which currently is
unknown.20 The rate of elimination of the biomarkers
also must be considered, especially because many cats
included in this study had concurrent CKD, which may
decrease the clearance of VEGF,21 NT-proBNP,14,22,23
and cTnI.24,25 For this reason, both healthy and CKD
cats were included as control groups. Increased plasma
VEGF concentrations have been reported in human
patients with CKD when compared to healthy controls,
and concentrations were higher with more advanced
CKD.26,27 In our study, large overlap was found among
plasma VEGF concentrations of hypertensive cats,
healthy cats, and cats with CKD, but cats with CKD
did not have significantly higher plasma VEGF concen-
trations compared to healthy cats. The concentration of
NT-proBNP also has been reported to increase with
decreasing glomerular filtration rate (GFR) in some
species.28 Cats with CKD included in our study did not
have significantly higher NT-proBNP concentrations
than did healthy cats, which conflicts with previously
published results.14 However, in the previous study, the
cats with CKD were in more advanced International
Renal Interest Society (IRIS) stages. The majority of
cats in our study were diagnosed in IRIS stage 2, which
could explain the absence of significant differences
among the groups. The cTnI concentrations were higher
in CKD, HT-ocular-TOD, and HT-noTOD cats when
compared to the healthy group. This difference is likely
to be because of underlying CKD in the hypertensive
cats. Previous studies that evaluated cTnI in cats with
CKD have reported concentrations above the reference
interval.29 Human patients with renal failure often have
increased cTnI concentrations.30 However, it is possible
that cats with CKD, like human patients, develop con-
current heart disease or suffer from uremic damage to
the heart, and whether the increase found in our study
is caused by increased production or decreased excre-
tion warrants further research.
It seems unlikely that any of the biomarkers studied
would change measurably because of the transient
increases in blood pressure that occur during a visit to
the clinic. Increases in VEGF occur rapidly in response
to stretch, deformation, and shear stress in cell cul-
ture,31 but take up to 3 days to increase in animals with
hypertension.32,33 Brain natriuretic peptide (BNP) gene
expression and mRNA levels increase rapidly (within
2 hours) with stretch and pressure overload, and BNP
gene expression increases after 2 hours of stretch in
mouse cardiac tissue specimens.34 The N-terminal
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Fig 5. Plasma N-terminal probrain natriuretic peptide (NT-proBNP) in hypertensive cats at visit hypertension was diagnosed (visit 1) and
first controlled visit on amlodipine treatment (defined as systolic blood pressure below 160 mmHg) (visit 2; for HT-ocular-TOD after
20  8 days and HT-noTOD 25  15 days). The median NT-proBNP concentration decreased by 60% in cats with evidence of hyperten-
sive ocular target organ damage (HT-ocular-TOD) and by 35% in cats without evidence of hypertensive retinopathy (HT-noTOD).
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fragment of BNP (NT-proBNP) is spliced off after BNP
secretion, and, because elimination of NT-proBNP is
much slower, it is considered a more suitable assessment
method for change in BNP in clinical patients. Because
of the slow elimination, the concentration in the blood
will reflect prevailing concentrations over a much longer
period than the active hormone.35 When inducing
necrosis in cell culture studies, cTnI release does not
occur until the cardiomyocytes are irreversibly damaged
(after >18 hours), whereas in the reversible phase, the
concentrations do not increase.36 A few studies have
described cTnI release from viable cardiomyocytes in
response to stretch, indicating that myocardial strain
rather than cell injury could lead to cTnI increases.37
Overall, however, the evidence suggests that increases in
cTnI do not occur rapidly with transient increases in
SBP.
In our study, VEGF appeared to hold the greatest
promise as a marker of ocular-TOD caused by hyper-
tension, but the marker did not prove to be significant
in the multivariable analysis. Plasma VEGF concentra-
tion was not increased in cats that were diagnosed with
hypertension in the absence of ocular-TOD. Vascular
endothelial growth factor has been proposed as a mar-
ker for hypertension in humans, but it is not yet clear
whether it is a marker of, or a player in, the develop-
ment of hypertension. Hypertensive human patients
have increased plasma VEGF concentrations compared
to normotensive controls.10,12,38,39 Plasma VEGF con-
centrations may increase with increasing pressure, and
the development of ocular-TOD could simply be caused
by higher pressure in the arteries and arterioles of target
organs. However, the SBP of cats without ocular-TOD
was not significantly lower than the SBP of cats with
ocular-TOD. It therefore seems more likely that those
cats with ocular-TOD have a different pathophysiologic
response to increased pressure than cats without ocular-
TOD or that the underlying pathophysiology for the
development of hypertension is different. Considering
the edematous ocular lesions often seen in hypertensive
cats,2 a permeability factor like VEGF may play a role
in the development of retinopathy and choroidopathy.
However, if a systemic response was damaging to the
retina, the damage is likely also to occur in other target
organs, such as the kidney, and cats with hypertensive
ocular-TOD did not have significantly higher plasma
creatinine concentrations or UPC than those without. It
therefore also is possible that certain cats in the HT-
noTOD group were incorrectly classified and that both
groups suffered similar hypertensive damage to their
kidneys.
If deranged angiogenesis underlies the hypertension
observed in cats with ocular-TOD, it could be accompa-
nied by increased plasma VEGF concentrations.40 In
human patients, VEGF has been reported to decrease
with a comparable duration of antihypertensive treat-
ment as that studied here.38 Plasma VEGF concentra-
tion did not decrease with effective antihypertensive
treatment in the cats in our study, something that
would have been expected to happen if VEGF was
increased as a physiologic response. This observation
could support a role for VEGF in the causation of
hypertensive ocular-TOD in cats. Additional studies
including a larger number of cats, both before and after
they develop hypertension with and without ocular-
TOD, are required to investigate this hypothesis.
Our study is the second to assess NT-proBNP con-
centrations in hypertensive cats.14 Other studies pub-
lished to date have evaluated NT-proBNP as a
biomarker of myocardial disease,41 and for differentia-
tion of cardiac and noncardiac causes of respiratory
distress.41 The concentration of NT-proBNP was not
found to be an independent predictor of hypertension
or ocular-TOD in the cats in our study, although many
cats had increased concentrations, including in the con-
trol groups. This finding could be a result of subclinical
heart disease, which is very prevalent in the feline popu-
lation.42,43 Up to 16% of cats have subclinical car-
diomyopathy,44 and therefore, exclusion of cats with
evidence of heart disease may have introduced bias.45
Furthermore, echocardiography cannot differentiate
between primary heart disease and secondary hypertro-
phy because of hypertension. Additionally, not having
the opportunity to perform echocardiography on all
cats is representative of general practice. It was there-
fore decided to keep all cats, including those with evi-
dence of severe hypertrophy on echocardiographic
assessment, with or without an increased NT-proBNP
concentration, in the study. Additionally, thyroid status
was assessed in all cats based on history and clinical
findings, but was not always based on TT4 measure-
ment. An important consideration in clinical practice is
that NT-proBNP concentrations are significantly
increased in hyperthyroidism.46,47
Limitations of our study that must be recognized are
that cats with primary cardiac disease with or without
occult hyperthyroidism could have been included. Tar-
get organ damage was determined by fundic examina-
tion. However, the eye is not the only organ susceptible
to hypertensive damage. The kidneys, brain, and heart
also are possible targets, most cats included in the HT-
noTOD group had CKD, and 3 cats had evidence of
severe hypertrophy on echocardiography. It is not pos-
sible to differentiate hypertrophy as a consequence of
primary cardiac disease versus that secondary to the
effects of systemic hypertension, and therefore, the car-
diac changes identified on echocardiography may have
reflected TOD. For this reason, 2 separate analyses
were performed—1 with the hypertensive cats grouped
together and 1 with the ocular-TOD cats separately.
A few studies describe NT-proBNP as a marker of
TOD in human medicine.4,48 Hypertensive cats with
ocular-TOD had significantly higher plasma concentra-
tions NT-proBNP than did healthy cats, but HT-
ocular-TOD cats did not have significantly different
NT-proBNP from HT-noTOD. Studies of humans have
reported similar results when comparing BNP and NT-
proBNP in patients with hypertension and TOD to
controls.49 The finding that HT-noTOD and HT-
ocular-TOD did not differ significantly is in contrast
with results previously presented,15 and might be
explained by the absence of a difference in SBP between
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the 2 groups included in our study. The concentration
of NT-proBNP significantly decreased in both hyperten-
sive groups with antihypertensive treatment, suggesting
that it may be useful to assess the efficacy of treatment.
Studies following cats over a longer period of time and
comparing animals in different SBP categories over time
would be a useful next step.
Cardiac troponins (cTns) historically have been
accepted as markers for cardiac injury and myocardial
cell necrosis.36,50 In cats included in our study, cTnI
was an independent predictor of hypertension, but not
of ocular-TOD. With treatment of hypertension, cTnI
did not decrease, which indicates that it is less useful
for assessing the effect of treatment. The human medi-
cal literature currently is still confusing, with most stud-
ies reporting increases in cTnI in hypertensive
patients,19,51,52 but a recent study reported decreased
cTnI concentrations in hypertensive HCM patients.53
Increased SBP can lead to cardiac remodeling, with ini-
tial hypertrophy, followed by apoptotic loss of car-
diomyocytes and fibrosis.54 Hypertension may lead to
some cardiomyocyte damage and necrosis, but the
majority of cells may not have a severely damaged sar-
colemma, and therefore, release of cTnI may occur in
an alternative manner. Indeed, cell culture studies have
confirmed that stimulation of integrins (mechanotrans-
ducing molecules in cardiomyocytes) leads to the release
of intact cTnI,37 and excised rat hearts put under
increased pressure secrete cTnI products independent of
ischemia.55 Stretch of cardiomyocytes therefore may
induce cTnI release, which may explain why, in our
study, cTnI was identified as an independent predictor
of hypertension. Despite cTnI being an independent
predictor of hypertension, the hypertensive cats did not
have significantly higher cTnI concentrations than did
the CKD cats. Most hypertensive cats (36 of 49) had
underlying CKD, and damage to the heart caused by
CKD is a potential explanation for the higher con-
centrations found in all groups when compared to
healthy cats. Additionally, effective antihypertensive
treatment did not decrease plasma cTnI concentration.
Cardiac troponin I has a long plasma half-life,16,56
but hyperthyroid cats undergoing radioactive iodine
treatment have decreased cTnI concentrations
3 months after treatment, indicating that the lack of
a decrease at the 5-month time point in our study
cannot be explained by the long half-life of cTnI.46,57
This observation strengthens the hypothesis that cTnI
is higher in all groups when compared to healthy cats
because of underlying CKD. Because CKD is a risk
factor for the development of hypertension,58 the
association between CKD and cTnI may have
resulted in the predictive relationship between cTnI
and hypertension.
The ultimate aim of identifying biomarkers would be
to develop a diagnostic test that can help veterinarians
in the challenging diagnosis of hypertension in the
absence of ocular-TOD. When assessing the ROC
curves (sensitivity and specificity), none of the biomark-
ers alone met the criteria to diagnose hypertension.59,60
When combining all 3 potential markers with an AUC
that was significantly different from the line of zero dis-
crimination, using a cutoff for VEGF of 76.1 pg/mL,
NT-proBNP of 134.5 pmol/L, and cTnI of 0.045 ng/
mL, the specificity can be increased to 96%. This is
however associated with a sensitivity of 31%. A combi-
nation of cTnI and VEGF has a specificity 88% and
sensitivity of 76% to diagnose hypertensive ocular-
TOD. One cannot argue in favor of replacing a nonin-
vasive method (retinal examination) with an invasive
blood test with a lower sensitivity and specificity. This
indicates that, although associated with blood pressure,
hypertension, and ocular-TOD, these biomarkers are
unlikely to be of clinical utility in the differentiation of
white coat from true hypertension when no ocular-TOD
is present.
In conclusion, plasma VEGF and cTnI concentra-
tions are independent predictors of hypertension. Vas-
cular endothelial growth factor may play a role in the
development of hypertension or ocular-TOD associated
with hypertension, and further research is warranted.
Both plasma cTnI and VEGF concentrations may be
indicative of less reversible tissue injury, and neither
factor decreased with antihypertensive treatment.
Plasma NT-proBNP concentration possibly could be
used to assess efficacy of antihypertensive treatment.
However, none of the biomarkers performed sufficiently
well in predicting ocular-TOD to serve as a clinical test
for hypertension or ocular-TOD.
Footnotes
a Parks Electronic Doppler Model 811B, Perimed UK, Bury St
Edmunds, UK
b Mistral 3000, Sanyo-Gallenkamp, Leicestershire, UK
c IDEXX Laboratories, Wetherby, Yorkshire, UK
d Istin, Pfizer, Kent, UK
e Canine VEGF Quantikine ELISA, R&D systems, Minneapolis,
USA
f GraphPad Prism version 6 for Windows, GraphPad Software, La
Jolla, California, USA and R Core Team (2013). R: A language
and environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria.
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